核素骨显像对诊断泌尿生殖系肿瘤骨转移的临床价值

采用核素骨显像方法合身骨显像诊断尿生殖系恶性肿瘤骨转移患者５８例。结果前列腺癌、膀胱癌、肾癌骨转移率分别为６７．７４％、７２．７３％和３１．２５％。认为核素骨显像对肿瘤骨转移的诊断具有方法简单等特点，较Ｘ线等检查方法更能早期发现骨转移肿瘤病例。     

血清PSA与前列腺癌骨转移的关系

目的:探讨血清前列腺特异抗原(PSA)预测前列腺癌骨转移的价值.方法:以全身核素骨显像为金标准,回顾性分析放免法测定的58例前列腺癌骨转移和63例非骨转移患者血清PSA水平与骨转移的关系.结果:血清PSA≤10/μg/L者骨转移的发生率极低,发生率为0.PSA≥20 μg/L者有骨转移的可能,骨转移的发生率为50%.PSA≥40/μg/L者骨转移的可能性极大,骨转移的发生率为68%.结论:对于新诊断而未治疗的前列腺癌的患者,PSA<10μg/L者无骨痛或病理性骨折时不必行全身核素骨显像检查.PSA≥20μg/L者应常规行全身核素骨显像检查,以早期确诊前列腺癌骨转移.     

18F-脱氧葡萄糖正电子发射计算机断层显像CT检查在前列腺癌诊断和分期中的应用价值

目的 评价18F-脱氧葡萄糖(18F-FDG)正电子发射计算机断层显像CT检查(PET/CT)在前列腺癌诊断和分期中的应用价值.方法 经手术或穿刺活检病理证实为前列腺癌患者40例,年龄52 ～ 78岁,平均67岁.其中T24例,T316例,T420例.行18F-FDG PET/CT及99Tcm-MDPECT骨显像检查,统计PET/CT显像对前列腺癌原发灶、淋巴结转移及骨转移诊断的敏感性,对比分析PET/CT显像及99Tcm-MDPECT骨显像对骨转移的诊断效果.结果 40例患者中,18F-FDG PET/CT检查显示前列腺局部结节状放射性浓聚17例,对原发灶诊断敏感性为43％.17例淋巴结转移患者中CT检查发现8例,18F-FDG PET/CT检查发现15例,诊断敏感性为88％,其中5例患者因PET/CT检查改变了临床分期以及治疗方案.18F-FDG PET/CT对骨转移诊断的敏感性与99Tcm-MDP骨显像相近,但特异性(95％)和准确率(96％)均明显高于99Tcm-MDP骨显像,其中6例患者因PET/CT检查改变了临床分期,2例改变了治疗方案.结论 18F-FDG PET/CT对前列腺癌淋巴结转移和骨转移有较高诊断价值,对前列腺的分期具有特殊优势,可为临床医生制定治疗方案提供可靠依据.     

骨形态发生蛋白-7在前列腺癌组织中的表达及意义

目的 研究骨形态发生蛋白-7(BMP-7)在前列腺癌(PCa)组织中的表达及意义.方法 经病理检查确诊PCa组织标本87例.患者平均年龄66(59～78)岁,术前或穿刺前血清总PSA(t-PSA)平均45.7(2.4～138.2)ng/ml.Gleason评分≤6分37例,7分18例,≥8分32例.临床分期:I期(T1a N0 M0)+Ⅱ期(T1b N0M0,T1cN0M0,T2N0M0)20例,Ⅲ期(T3N0M0)20例.Ⅳ期(T4N0M0,TxN1M0,TxN0M1)47例,其中TxN0M1 45例.根据核素骨扫描或正电子发射计算机体层成像CT检查结果分为:PCa无骨转移42例,PCa伴骨转移45例.以30例BPH组织标本为对照,患者平均年龄68(57～88)岁.免疫组织化学PV法检测BMP-7在PCa组织和BPH组织中的表达,统计学分析2组及PCa组内表达差异,PCa组织中BMP-7与血清t-PSA相关性采用Pearson相关性分析. 结果BPH组织中BMP-7表达吸光度A值为70.55±5.41,PCa组织中为70.47±6.18,2者比较差异无统计学意义(P>0.05).PCa无骨转移组BMP-7表达吸光度A值为65.94±1.76,伴有骨转移组为74.80±5.76,2者比较差异有统计学意义(P<0.05).Gleason评分≤6分者吸光度A值为65.96±1.56,7分者为65.83±2.75,≥8分者为78.06±1.39.≤6分和7分者分别与≥8分相比,BMP-7表达A值差异有统计学意义(P<0.05).临床分期编组中Ⅰ期+Ⅱ期BMP-7表达A值为65.86±1.72,Ⅲ期为65.87±1.85,Ⅳ期为74.49±5.83,Ⅰ期+Ⅱ期和Ⅲ期分别与Ⅳ期相比,差异有统计学意义(P<0.05).PCa组织中BMP-7表达A值与血清t-PSA值呈正相关关系(r=0.77,P<0.05).结论 病理Gleason高评分、临床分期、已发生骨转移的PCa组织中高表达BMP-7,BMP-7表达水平与血清t-PSA具有正相关性,提示BMP-7可能是促进PCa细胞发生骨转移的重要细胞因子之一.     

核医学显像对不明性质颈痛患者的诊断价值

目的 探讨核医学显像在诊断不明性质颈痛中的价值.方法 70例不明性质颈痛患者,X线、CT或MRI结果提示骨质破坏或占位性病变,无法确定病变性质,拟手术治疗入院.为明确诊断,行99m Tc-亚甲基二磷酸盐(99mTc-MDP)全身骨显像.显像后1周内行手术或病灶穿刺活检,获得病理学结果.10例骨显像多发骨转移瘤的患者进行了符合线路18F-脱氧葡萄糖(FDG)肿瘤代谢显像.结果 骨显像阳性62例.33例颈部单发病灶,其中原发恶性肿瘤4例,转移瘤6例,良性病变23例.29例为多发病灶,其中转移瘤24例.25例患者骨显像后改变了治疗方案.10例转移瘤患者中的7例18F-FDG肿瘤代谢显像找到了原发病灶.结论 全身骨显像应作为诊断不明性质颈痛的重要辅助手段.18F-FDG肿瘤代谢显像与全身骨显像联合应用对于不明性质颈痛的明确诊断,分期,指导临床治疗有着重要的意义.     

肺癌、乳腺癌核素骨显像的特点分析

目的通过对2036例肺癌、乳腺癌患者全身骨显像进行分析,研究核素骨显像对诊断转移性骨肿瘤是否具有很高的灵敏度。方法对1196例肺癌、840例乳腺癌患者,采用常规扫描检查方法。结果肺癌、乳腺癌骨转移发生率分别为54.51%和36.78%,肺癌骨转移单发性为30.67%,多发性为69.33%。乳腺癌单发性52.43%,多发性为47.57%。结论肺癌、乳腺癌骨转移好发部位以肋骨、胸骨、胸椎及腰椎为主。关于骨转移发展规律,由于对疾病的早期发现和治疗,核素治疗骨转移,疗效显著,全身骨显像对恶性肿瘤的治疗方案及治疗效果的评价起到决定作用。     

2010年第7版肾癌新分期的应用效果评估

目的 探讨2010年第7版肾癌新分期系统的临床应用效果.方法 收集1981年1月至2003年12月手术治疗的695例肾癌患者的存档资料,分别按照国际抗癌联盟及美国癌症联合会2002年第6版和2010年第7版肾癌分期系统进行临床病理分期,观察不同分期患者的生存情况,应用Kaplan-Meier法、Log-rank检验、Cox比例回归风险模型进行统计学分析.结果 按照新分期系统,第6版分期系统中T2期171例中120例归入T2a期,51例归入T2b期,13例因肿瘤侵犯肾上腺而归入T4期,3例并发肾静脉瘤栓者归入T3a期.按第6版分期系统,T3a期中单纯肾周脂肪阳性患者的预后与单纯肾上腺阳性患者比较差异有统计学意义(P=0.008),单纯肾上腺阳性患者预后与T4期肾癌患者比较差异无统计学意义(P=0.412).新分期系统中,T2b与T3a期预后差异无统计学意义(P=0.741),将T3a期以7 cm为分界点分类后,T3a期(肿瘤最大直径≤7 cm)与T2a期的预后相近(P=0.342),T3a期(肿瘤最大直径＞7 cm)预后与T2b比较差异有统计学意义(P=0.019).结论 第7版肾癌分期系统显示了更好的分期特异性.     

18F-FDG PET/CT显像在肾癌中的临床应用价值

目的:评价18F-脱氧葡萄糖(18F-fluorodeoxyglucose,18F-FDG)正电子发射计算机断层扫描(PET)/CT显像对肾癌诊断和治疗方案选择的临床应用价值.方法:回顾性分析56例临床诊断为肾癌患者的全身18F-FDG PET/CT和CT平扫加增强扫描的影像学资料.比较两者对肾癌的诊断价值.结果:56例患者中,经手术病理检查实为肾癌者47例.其余9例因18F-FDG PET/CT显像发现有转移病灶者放弃手术.18F-FDG;PET/CT 榆古敏感度为80.4%;CT平扫加增强扫描的敏感度为92.9%.9例转移病例中,3例为腹膜后淋巴结转移,3例两肺多发转移,2例骨转移并肝转移,1例伴有下腔静脉和肾静脉癌栓形成,而CT平扫加增强扫描仅发现1例肾静脉和下腔静脉痛栓形成.结论:18F-FDG PET/CT显像对诊断原发性肾癌的敏感性不如CT,但对淋巴结转移及远处转移的诊断优于CT,对肾癌的分期、治疗方案的选择及预后的判断有重要意义.     

核素全身骨显像鉴别诊断肋脊关节骨转移瘤

目的观察核素全身骨显像中肋脊关节放射性浓集灶的影像学特点及其对骨转移瘤的鉴别诊断价值。方法回顾性分析60例确诊为恶性肿瘤、骨显像示肋脊关节受累者的临床、影像及病理资料。以同期高分辨率CT、临床随访及病理结果为标准,分析核素全身骨显像中肋脊关节骨异常放射性浓集的特点,探讨其诊断灵敏度和特异度。结果 60例中,54例(54/60,90.00%)存在骨转移瘤。骨显像示肋脊关节处放射性异常浓集灶呈中心靠肋骨侧和中心靠椎体侧,呈现为横向和纵向条形。将中心靠肋骨侧浓集定义为骨转移瘤阳性,骨显像的灵敏度与特异度分别为59.26%(32/54)和83.33%(5/6);将横向条形浓集定义为骨转移瘤阳性,灵敏度与特异度分别为29.63%(16/54)和100%(6/6);将中心靠肋骨侧浓集或横向条形浓集均定义为骨转移瘤阳性,灵敏度与特异度分别为88.89%(48/54)和83.33%(5/6)。结论核素全身骨显像显示肋脊关节处放射性异常浓集,尤其当病灶中心靠肋骨侧和呈横向条形浓聚时,应高度警惕骨转移瘤。     

上海仁济医院肾癌数据库资料分析

目的 探讨肾癌临床、病理、分期、分级与预后特征. 方法 分析2003年至2005年上海仁济医院泌尿科肾癌数据库435例患者临床和病理资料.采用WHO 1997年肾实质上皮性肿瘤组织学分类标准、2002年ATCC的TNM分期和临床分期、1982年Fuhrman病理分级.采用Kaplan-Meier法和Logrank检验对57例获随访的晚期患者行生存分析和预后因素判断. 结果 435例患者中,遗传性VHL病肾癌10例(2.4%)、散发性肾透明细胞癌372例(85.5%)、乳头状癌13例(3.0%)、嫌色细胞癌18例(4.1%)、集合管癌4例(0.9%)、嗜酸性细胞腺瘤4例(0.9 %)、未分类肾癌.14例(3.2%).行根治性肾切除术335例(77.0%),保留肾单位手术74例(17.0%),姑息性肾切除等手术26例(6.0%).遗传性VHL病肾癌均为双肾癌伴多发囊肿,临床分期Ⅰ期7例、Ⅱ期3例,病理分级Ⅰ级6例、Ⅱ级4例,基因测序均存在VHL基因突变,平均随访28.6个月,患者无肿瘤局部进展或转移,但4例患者出现同侧或双侧肿瘤再发.嫌色细胞癌临床分期均为Ⅰ期,病理分级Ⅰ级5例,Ⅱ级13例,平均随访19.8个月均存活,无肿瘤转移或复发.集合管癌临床分期均为Ⅰ期,病理分级均为Ⅲ级,平均生存时间11.3个月.肾透明细胞癌和乳头状癌临床分期Ⅰ期260例(67.6%)、Ⅱ期64例(16.6%)、Ⅲ期32例(8.3%)、Ⅳ期29例(7.5%),其中T1a 147例(38.2%)、T1b 113例(29.4 %);病理分级Ⅰ级124例(32.2%)、Ⅱ级219例(56.9%)、Ⅲ级40例(10.4%)、Ⅳ级2例(0.5%).57例晚期肾癌患者中位生存时间(16.0±1.3)个月,1年生存率55.0%,2年生存率31.0%.预后因素分析显示,临床分期、肿瘤大小、淋巴结转移、远处转移和病理分级是晚期肾癌解剖水平和组织学水平的预后影响因素. 结论 不同组织学亚型的肾癌生物学特征存在较大差异,遗传性VHL病肾癌存在基因突变,常为双侧、多中心、低Fuhrman分级透明细胞癌,易再发不易转移.肾嫌色细胞癌预后较好,而集合管癌预后差.在解剖水平和组织学水平,TNM分期、肿瘤大小、淋巴结转移、远处转移和肾癌病理分级是晚期肾癌的预后影响因素.     

THE DIAGNOSTIC VALUE OF BONE SCAN IN PATIENTS WITH RENAL CELL CARCINOMA

PURPOSE: Bone scan is performed as part of the evaluation of bone metastasis. We assessed the diagnostic value of bone scan in patients with renal cell carcinoma. MATERIALS AND METHODS: Bone scan was performed at presentation in 205 patients with confirmed renal cell carcinoma. Abnormal hot areas were further evaluated by x-ray, computerized tomography or surgery. RESULTS: Of the 56 patients (27%) with an abnormal bone scan 32 (57%) had osseous metastatic lesions. Overall bone metastasis was present in 34 of the 205 patients (17%). Bone scan had 94% sensitivity and 86% specificity. Of the 124 patients with clinically localized, stages T1-2N0M0 disease exclusive of bone metastasis 6 (5%) had bone metastasis only, whereas 28 of 81 (35%) with locally advanced or metastatic disease had bone metastasis, including 12 (35%) who complained of bone pain and 19 (56%) who presented with other symptoms due to local tumor growth or metastasis at other sites. Three patients (9%) were asymptomatic. There was osseous metastasis without other metastasis, enlarged regional lymph nodes or bone pain in 7 patients, including 1 with stage T1b (2% of all with that stage), 2 with stage T2 (5%), 1 with stage T3a (4%), 1 with stage T3b (6%), 1 with stage T3c (14%) and 1 with stage T4 (6%) disease. CONCLUSIONS: Bone scan may be omitted in patients with stages T1-3aN0M0 tumors and no bone pain because of the low proportion of missed cases with bone metastasis.     

Value of routine radionuclide bone scans in renal cell carcinoma

Radionuclide bone scans were obtained as part of the routine evaluation of 85 patients with renal cell carcinoma. Twenty-nine patients (34%) were found to have metastatic disease at presentation. Bone scans were abnormal in 27 of these 29 patients for a sensitivity of 93 per cent; of the remaining 56 without metastatic disease, 48 had normal bone scans for a specificity of 86 per cent. In all patients whose abnormal bone scans indicated metastatic disease, there were either clinical signs (bone pain), laboratory findings (elevated alkaline phosphatase), or routine radiographic procedures (chest roentgenogram, intravenous pyelogram, or angiogram) suggesting disease metastatic to bone. Although bone scanning was useful for confirming clinically or radiographically suspected metastatic disease, it did not influence the staging of the renal cell carcinoma in any patient. We therefore conclude that bone scans should be used to confirm the presence and to determine the extent of osseous metastases in patients with renal cell carcinoma but are unnecessary as a routine staging procedure.     

Evaluation of bone metastases from renal cell carcinoma

Forty-two cases of bone metastasis from renal cell carcinoma were examined. Thirty of the cases had bone metastases at the time of renal cell carcinoma. Bone metastasis appeared after treatment of the primary site in 12 cases. Fifteen cases had only bone metastasis and another 27 had metastasis in multiple organs. The total cause-specific survival curve of these patients was 10% at 5 years. All patients with bone metastases died of cancer within 5 years after the bone metastases had developed. There was no significant difference in the survival rate between patients with bone metastases and patients with lung metastases. We investigated the prognostic value of laboratory studies in bone metastases of renal cell carcinoma. However, no significant markers were detected for bone metastases. The 6 patients were treated with decompressed laminectomy (2), wide resection (3) and excision of the metastatic lesions (3). The quality of life was improved in all the patients although they died of cancer.     

γ-GT和ALP在预测肾癌转移中的作用

为了明确γ-GT及ALP在预测肾癌转移中的作用,我们回顾性研究了15例肾癌转移病人的γ-GT及ALP检测结果,分析其与转移部位、病理类型的关系,并与24例无临床转移的肾癌病人作对照研究。结果发现:转移组中有80％的患者γ-GT增高,40％出现ALP异常,明显高于对照组(分别为12.5％及O,P<0.001)。另外,有肝转移的病人γ-GT全部升高,而骨转移组ALP增高的比例又明显高于其它转移部位的患者;就病理类型而言,透明细胞癌γ-GT增高的比例明显高于其它类型。说明γ-GT可作为预测肾癌转移的一个指标,ALP则对有骨转移的病人有较好的补充作用。     

胆囊癌的CT分级和手术可切除性评价

目的 本文探讨胆囊癌的CT分级对胆囊癌手术切除性的价值.方法 回顾性分析47例经手术病理证实的胆囊癌的CT表现,进行CT分级并评估其手术可切除性.结果 术前CT分级,Ⅰ级3例,占6.4%(3/47),Ⅱ级14例,占29.8%(14/47),Ⅲ级10例,占21.2%(10/47),Ⅳ级20例,占42.6%(20/47).术后病理证实为Ⅰ级3例,占6.4%,Ⅱ级14例,占29.8%, Ⅲ级8例,占17.0%,Ⅳ级22例,占42.6%,术前CT分级符合率为91.5%(43/47).胆囊癌的手术方法 分为根治性手术、姑息性手术和剖腹探查术.本文47例中行根治性手术30例,其中Ⅰ级3例,占10%(3/30),Ⅱ级14例,占46.7%(14/30),Ⅲ级7例,占23.3%(4/30),Ⅳ级6例,占20.0%(6/30);行姑息性手术15例,其中Ⅲ级1例,占6.7%(1/24),Ⅳ级14例,占93.3%(14/15);剖腹探查术2例,均为Ⅳ级.结论 胆囊癌CT分级可能有助于临床选择最佳治疗方案.     

肾和肾上腺恶性肿瘤合并下腔静脉瘤栓的外科治疗

目的 提高肾和肾上腺恶性肿瘤伴下腔静脉瘤栓的治疗效果.方法 1985年1月至2008年4月收治肾和肾上腺恶性肿瘤合并下腔静脉瘤栓患者29例,均经彩色多普勒超声、CT及MRI检查确诊.瘤栓分型:I型7例、Ⅱ型10例、Ⅲ型8例、Ⅳ型4例.其中肾上腺肿瘤4例,肾肿瘤25例.TNM分期:T2NoMo 23例,T2N1Mo 1例,T2N1M1 1例,T3N.Mo 1例,T3N1M1 2例,T3N2Mo 1例.肿瘤平均直径8.7(4.O～16.0)cm.瘤栓平均长度:I型3.2(2.5～4.O)cm,Ⅱ型5.3(4.5～6.O)cm,Ⅲ型8.2(6.5～9.0)cm,IV型15.1(12.O～18.5)cm.29例均在全麻下行肾或肾上腺肿瘤根治性切除加下腔静脉瘤栓切除术.结果 29例手术均获成功.术后病理报告:肾透明细胞癌18例、肾肉瘤样癌3例、肾乳头腺癌2例、肾细胞癌(未分化型)1例、肾颗粒细胞癌1例、肾上腺皮质癌3例、肾上腺转移性恶性黑色索瘤1例.失访3例,余26例平均随访35(0～62)个月,患者3年生存率58%(15/26),5年生存率42%(11/26).T2、T3患者3年生存率分别为64%(14/22)、25%(1/4),5年生存率分别为45%(10/22)、25%(1/4).I、II、Ⅲ和Ⅳ型瘤栓患者3年生存率分别为4/6、5/8、5/8和1/4,5年生存率分别为3/6、4/8、3/8和1/4.膈肌以下瘤栓患者3、5年生存率分别为64%(14/22)、45%(10/22),膈肌以上瘤栓患者分别为1/4、1/4.肾和肾上腺恶性肿瘤伴下腔静脉瘤栓无转移患者的3、5年生存率为12/18、9/18,有转移患者分别为3/8、2/8.3例术前出现转移患者生存时间分别为6、10、22个月.结论 根治性肿瘤切除和下腔静脉取栓治疗无淋巴和远处转移的肾和肾上腺恶性肿瘤合并下腔静脉瘤栓效果良好;即使存在远处转移,外科手术仍可以提高患者生活质量,延长患者生存期.     

Skeletal metastases in 102 patients evaluated before surgery for renal cell carcinoma.

During a 3-year period a consecutive series of 102 patients were treated for renal cell carcinoma at one urological unit. Thirty-three patients (32.4%) had metastatic spread, but bone metastases were found in six patients only, i.e. 5.9% of the whole series and 18.2% of the patients with metastases preoperatively. The bone metastases had in all six patients given local symptoms first indicating radiography, and thereafter radionuclide scintigraphy of the entire skeleton. Bone scintigraphy performed merely by routine in 70 patients did not reveal one single case of bone metastasis. Only one patient had a solitary bone metastasis, and this metastasis was considered inoperable because of its location and size and the patient's age. The decision about nephrectomy was not in any case altered by the finding of bone metastases. Solitary bone metastasis must be diagnosed early since they may be radically removed. Routine scintigraphy of the skeleton in symptomless patients, however, has a low yield. Screening for skeletal metastases may therefore be best performed by careful physical examination and history-taking.     

带血管蒂豌豆骨瓣移位治疗月骨缺血性坏死的中长期疗效评估

目的 评估带血管蒂豌豆骨移位治疗月骨缺血性坏死的中长期疗效.方法 1993年7月至2005年6月,采用月骨切除带血管蒂豌豆骨移位治疗月骨缺血性坏死患者11例,男6例,女5例;年龄20～67岁,平均(41.0±14.3)岁.Lichtman月骨缺血性坏死分期:Ⅲa期4例,Ⅲb期5例,Ⅳ期2例.末次随访时评估腕痛主观感受、视觉模拟评分(visual analogue scale,VAS)、患侧腕关节活动度(range of motion,ROM)、握力、Cooney腕关节功能评分及影像学变化.结果 患者随访61～202个月,平均(104.1±48.4)个月.10例患者腕痛缓解,7例达到基本无痛.疼痛VAS评分(2.2±1.9)分.患侧腕ROM为健侧的65.3%,握力为健侧的84.3%.Cooney腕关节功能评分优1例、良7例、可2例、差1例,优良率72.7%.X线片显示8例豌豆骨植入位置正常,2例向掌侧移位,1例向尺侧移位,舟豌豆间隙增宽;6例豌豆骨有正常骨小梁结构,3例萎缩变扁,2例有硬化改变;3例有骨关节炎改变.腕高比值、Nattrass指数较术前明显降低,桡舟角较术前增大,差异有统计学意义.结论 采用月骨切除带血管蒂豌豆骨移位是治疗Ⅲ～Ⅳ期月骨缺血性坏死的一种有效方法.术后虽可出现腕骨塌陷,但患者主观满意度高,握力好.

Abstract：

Objective To evaluate the long-term efficacy of vascularized pisiform transfer for patients with Kienb(o)ck's disease in Lichtman stages Ⅲ-Ⅳ. Methods Eleven patients were reviewed to analyze results after lunate resection and vascularized pisiform transfer for Lichtman stages Ⅲ and Ⅳ. There were six men and five women. Age ranged from 20 to 67 years with a average of 41.0±14.3 years. According to Lichtman stage. There were 4 cases in stage Ⅲa, 5 cases in stage Ⅲb, and 2 cases in stage Ⅳ. Assessment criteria included subjective assessment of pain, visual analogue scale (VAS), range of motion (ROM), grip power,Cooney wrist score and radiographic changes on each follow-up visit. The radiographic changes including pis iform bone location, shape, sclerosis change, osteoarthritis, carpal height ratio, Nattrass index, Radioscaphoid angle and ulnar variance were recorded. Results The follow-up periods of all of cases were 61-202 months,with an average of 104.1 months. Pain had improved in 10 patients and disappeared in 7 cases. The VAS score was 2.2±1.9 at follow-up visit. Range of motion of injured wristw as only 65.3% of opposite side. Grip power was 84.3% of the contralateral hand. According to Cooney score, the results were excellent in 1 case, good in 7cases, fair in 2 cases and poor in 1 case, with the excellent and good rate of 72.7%. Radiologically, 8 cases had normal position of the pisiform bone, 2 had volar displacement and 1 had ulnar displacement which leaded to widen scaphopisiform space. Six pisiform bones had normal trabecular structure, three had degenerative changes. Bone sclerosis was seen in 2 cases and osteoarthritis was found in 3 patients. Compared with radiographic parameter before surgery, carpal height ratio and Nattrass index significantly lowered and radioscaphoid angle significantly increased. Conclusion Lunate resection and vascularized pisiform transfer is an effective method for Kienb(o)k′s disease in stages Ⅲ-Ⅳ. Although carpal collapse appeared postoperatively,the results show high patient satisfaction and good function after vascularized bone transplantation.